Martin Auster
Stock Analyst at Raymond James
(2.54)
# 2,386
Out of 5,044 analysts
55
Total ratings
53.66%
Success rate
12.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Downgrades: Market Perform | n/a | $69.65 | - | 2 | Oct 27, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $56 → $59 | $66.62 | -11.44% | 1 | Oct 21, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $85.00 | +27.06% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $205.71 | +31.74% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $23.63 | +48.12% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $481.59 | -11.96% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $51.86 | +131.39% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $34.59 | +203.56% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $9.36 | +177.78% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $5.49 | +2,085.79% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $725 → $300 | $7.47 | +3,916.06% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $31.41 | +84.65% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $455.32 | -56.95% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $1.59 | +6,063.52% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $166.95 | -64.06% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $29.27 | +122.07% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $23.45 | +211.30% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $5.38 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $70.59 | +10.50% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.87 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $10.26 | +319.10% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $13.12 | +60.06% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $36.12 | -55.70% | 1 | May 7, 2020 |
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $69.65
Upside: -
BridgeBio Pharma
Oct 21, 2025
Maintains: Outperform
Price Target: $56 → $59
Current: $66.62
Upside: -11.44%
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $85.00
Upside: +27.06%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $205.71
Upside: +31.74%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $23.63
Upside: +48.12%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $481.59
Upside: -11.96%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $51.86
Upside: +131.39%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $34.59
Upside: +203.56%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $9.36
Upside: +177.78%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $5.49
Upside: +2,085.79%
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $7.47
Upside: +3,916.06%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $31.41
Upside: +84.65%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $455.32
Upside: -56.95%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.59
Upside: +6,063.52%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $166.95
Upside: -64.06%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $29.27
Upside: +122.07%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $23.45
Upside: +211.30%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $5.38
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $70.59
Upside: +10.50%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $2.87
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $10.26
Upside: +319.10%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $13.12
Upside: +60.06%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $36.12
Upside: -55.70%